Marie‐Luise Berres

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

Marie‐Luise Berres, Karen Phaik Har Lim, Tricia Peters et al. · The Journal of Experimental Medicine · 2014 · 430 citations · Full text

Immunology, Immune Regulation, Pathology +24

Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool

Stefan Jordan, Navpreet Tung, María Casanova-Acebes et al. · Cell · 2019 · 425 citations · Full text

Inflammation, Autoimmune Disease, Immune Regulation +6

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

Oncology, Hepatology, Medicine +10

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

Marie‐Luise Berres, Rory R. Koenen, Anna Rueland et al. · Journal of Clinical Investigation · 2010 · 257 citations · Full text